{
    "name": "teriflunomide",
    "comment": "Rx",
    "other_names": [
        "Aubagio"
    ],
    "classes": [
        "Multiple Sclerosis Treatments",
        "Pyrimidine Synthesis Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/aubagio-teriflunomide-999771",
    "pregnancy": {
        "common": [
            "Contraindicated for use in pregnant women and females of reproductive potential not using effective contraception because of potential for fetal harm based on animal data",
            "Exclude pregnancy before initiating treatment in females of reproductive potential; advise females to notify their healthcare provider immediately if pregnancy occurs or is suspected during treatment",
            "Discontinue treatment in female who wish to become pregnantand undergo accelerated elimination procedure to decrease plasma concentration of teriflunomide to less than 0.02 mg/L (0.02 mcg/mL); use effective contraception until is verified that plasma concentrations of teriflunomide are less than 0.02 mg/L (0.02 mcg/mL), which are expected to have minimal embryofetal risk",
            "If patient becomes pregnant during therapy, stop treatment, inform patient of potential risk to fetus, and perform accelerated drug elimination procedure to achieve plasma concentrations of less than 0.02 mg/L (0.02 mcg/mL); refer patient to obstetrician/gynecologist, preferably experienced in reproductive toxicity, for further evaluation and counseling"
        ],
        "specific": [
            {
                "type": "Pregnancy exposure registry",
                "description": [
                    "Registry monitors pregnancy outcomes in women exposed to therapy during pregnancy; healthcare providers and patients are encouraged to report pregnancies by calling 1-800-745-4447, option 2"
                ]
            },
            {
                "type": "Males",
                "description": [
                    "Drug is detected in human semen; animal studies to specifically evaluate risk of male mediated fetal toxicity have not been conducted; to minimize any possible risk, men not wishing to father a child and their female partners should use effective contraception",
                    "Discontinue therapy in men wishing to father a child and either undergo an accelerated elimination procedure or wait until verification that the plasma teriflunomide concentration is less than 0.02 mg/L (0.02 mcg/ml)",
                    "To minimize any possible risk, men not wishing to father a child and their female partners should use effective contraception"
                ]
            }
        ]
    },
    "lactation": null,
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Hepatotoxicity",
                    "description": [
                        "Clinically significant and potentially life-threatening liver injury, including acute liver failure requiring transplant, reported",
                        "Concomitant use of teriflunomide with other potentially hepatotoxic drugs may increase the risk of severe liver injury",
                        "Obtain transaminase and bilirubin levels within 6 months before initiating therapy; monitor ALT levels at least monthly for 6 months after starting therapy",
                        "If drug-induced liver injury is suspected, discontinue treatment and start an accelerated elimination procedure with cholestyramine or charcoal",
                        "Contraindicated in patients with severe hepatic impairment; patients with pre-existing liver disease may be at increased risk of developing elevated serum transaminases during treatment"
                    ]
                },
                {
                    "type": "Embryofetal toxicity",
                    "description": [
                        "Use is contraindicated in pregnant women and in females of reproductive potential who are not using effective contraception because of the potential for fetal harm",
                        "Teratogenicity and embryo lethality occurred in animals at plasma teriflunomide exposures lower than that in humans",
                        "Exclude pregnancy before initiating treatment in females of reproductive potential",
                        "Females of reproductive potential should use effective contraception during treatment and during an accelerated drug elimination procedure after treatment",
                        "Stop teriflunomide and use an accelerated drug elimination procedure if patient becomes pregnant"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "History of hypersensitivity reaction to teriflunomide, leflunomide, or excipients ",
                "Severe hepatic impairment",
                "Pregnancy",
                "Current leflunomide treatment"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Risk of malignancy, particularly lymphoproliferative disorders, is increased with use of some immunosuppressive medications; there is potential for immunosuppression with this drug; no apparent increase in the incidence of malignancies and lymphoproliferative disorders reported in clinical trials, but larger and longer-term studies would be needed to determine whether there is an increased risk of malignancy or lymphoproliferative disorders with therapy",
                "No clinical data available on efficacy and safety of live vaccinations in patients receiving therapy; vaccination with live vaccines is not recommended; the long half-life of the drug should be considered when contemplating administration of a live vaccine after stopping therapy",
                "May take an average of 8 months to clear drug from plasma; consider accelerated elimination with cholestyramine or activated charcoal",
                "Decreases in white blood cell count and platelet count have been observed; a recent CBC should be available before starting teriflunomide; monitor for signs and symptoms of infection; consider suspending treatment with teriflunomide in case of serious infection; do not start teriflunomide in patients with active infections",
                "Not recommended for patients with serious immunodeficiency; do not initiate treatment in patients with active acute or chronic infections",
                "Peripheral neuropathy, including polyneuropathy and mononeuropathy, have been reported; evaluate patient and consider discontinuing therapy; if a patient taking drug develops symptoms consistent with peripheral neuropathy, such as bilateral numbness or tingling of hands or feet, consider discontinuing therapy and performing accelerated elimination procedure",
                "May cause an increase in renal uric acid clearance and decreases in serum uric acid",
                "Use caution in hyperkalemia",
                "Anaphylaxis and severe allergic reactions reported; signs and symptoms have included dyspnea, urticaria, and angioedema including lips, eyes, throat, and tongue; inform patients of signs and symptoms of anaphylaxis and angioedema",
                "May increase blood pressure; measure blood pressure at treatment initiation and monitor blood pressure during treatment; elevated blood pressure should be appropriately managed during treatment",
                "Interstitial lung disease may be fatal and may occur acutely at any time during therapy with a variable clinical presentation; new onset or worsening pulmonary symptoms, such as cough and dyspnea, with or without associated fever, may be a reason for discontinuation of therapy and for further investigation as appropriate; if discontinuation of the drug is necessary, consider initiation of accelerated elimination procedure",
                "Pancreatitis reported; if pancreatitis is suspected, discontinue teriflunomide and start an accelerated elimination procedure",
                "Cases of tuberculosis reported; prior to initiating therapy, screen patients for latent tuberculosis infection with a tuberculin skin test or with a blood test for mycobacterium tuberculosis infection",
                " "
            ],
            "specific": [
                {
                    "type": "Hepatotoxicity",
                    "description": [
                        "Clinically significant and potentially life-threatening liver injury, including acute liver failure requiring transplant, reported in patients receiving therapy in the postmarketing setting; patients with pre-existing liver disease and patients taking other hepatotoxic drugs may be at increased risk for developing liver injury when taking this drug; clinically significant liver injury can occur at any time during therapy",
                        "Patients with pre-existing acute or chronic liver disease, or those with serum alanine aminotransferase (ALT) greater than two times upper limit of normal (ULN) before initiating treatment, should not normally be treated with this drug",
                        "Obtain serum transaminase and bilirubin levels within 6 months before initiation of therapy; monitor ALT levels at least monthly for six months after starting treatment; consider additional monitoring when therapy administered with other potentially hepatotoxic drugs",
                        "Consider discontinuing therapy if serum transaminase increase (>3x ULN) is confirmed; monitor serum transaminase and bilirubin, particularly in patients who develop symptoms suggestive of hepatic dysfunction, such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, or jaundice and/or dark urine",
                        "If liver injury suspected to be therapy-induced, discontinue drug and start an accelerated elimination procedure and monitor liver tests weekly until normalized; if drug-induced liver injury is unlikely because some other probable cause found, resumption of therapy may be considered"
                    ]
                },
                {
                    "type": "Accelerated elimination of teriflunomide",
                    "description": [
                        "This drug is eliminated slowly from plasma; without accelerated elimination procedure, it takes on average 8 months to reach plasma concentrations < 0.02 mg/L, although because of individual variations in drug clearance it may take as long as 2 years",
                        "An accelerated elimination procedure could be used at any time after discontinuation of treatment; elimination can be accelerated by either of the following procedures:  ",
                        "Administration of cholestyramine 8 g q8hr for 11 days; if cholestyramine 8 g TID not well tolerated, cholestyramine 4 g TID can be used",
                        "Administration of 50 g oral activated charcoal powder every 12 hours for 11 days",
                        "If either elimination procedure is poorly tolerated, treatment days do not need to be consecutive unless there is need to lower teriflunomide plasma concentration rapidly",
                        "At end of 11 days, both regimens successfully have accelerated teriflunomide elimination, leading to more than 98% decrease in teriflunomide plasma concentrations; use of accelerated elimination procedure may potentially result in return of disease activity if patient had been responding to treatment"
                    ]
                },
                {
                    "type": "Skin reactions",
                    "description": [
                        "Cases of serious skin reactions, including cases of Stevens-Johnson syndrome (SJS) and a fatal case of toxic epidermal necrolysis (TEN), reported",
                        "Drug reaction with eosinophilia and systemic symptoms (DRESS), also known as multiorgan hypersensitivity, has occurred with therapy; DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy and/or facial swelling, in association with other organ system involvement, such as hepatitis, nephritis, hematologic abnormalities, myocarditis, or myositis, sometimes resembling an acute viral infection",
                        "Eosinophilia is often present; this disorder is variable in itsexpression, and other organ systems not noted here may be involved; it is important to note that early manifestations of hypersensitivity (eg, fever, lymphadenopathy) may be present even though rash is not evident; if such signs or symptoms are present, the patient should be evaluatedimmediately",
                        "Inform patients of signs and symptoms that may signal a serious skin reaction; instruct patients to discontinue therapy and seek immediate medical care should these signs and symptoms occur ",
                        "Unless reaction is clearly not drug-related, discontinue therapy and begin an accelerated elimination procedure immediately; in such cases, patients should not be re-exposed to drug",
                        "Early manifestations of hypersensitivity (eg, fever, lymphadenopathy) may be present even though rash is not evident; if such signs or symptoms are present, the patient should be evaluated immediately",
                        "Discontinue therapy unless an alternative etiology for the signs or symptoms is established, and begin an accelerated elimination procedure immediately; in such cases, patients should not be re-exposed to drug"
                    ]
                },
                {
                    "type": "Bone Marrow Effects / Immunosuppression Potential",
                    "description": [
                        "Cases of thrombocytopenia, including rare cases with platelet counts < 50,000/mm",
                        "3",
                        ", reported in postmarketing setting; obtain a complete blood cell count (CBC) within 6 months before initiation of treatment; further monitoring should be based on signs and symptoms suggestive of bone marrow suppression",
                        "A mean decrease compared to baseline in white blood cell (WBC) count of approximately 15% (mainly neutrophils and lymphocytes) and in platelet count of approximately 10% observed",
                        "Most reports confounded by concomitant immunosuppressant therapy and/or comorbid illness which, in addition to rheumatoid disease, may predispose patients to infection"
                    ]
                },
                {
                    "type": "Risk of infection",
                    "description": [
                        "Patients with active acute or chronic infections should not start treatment until infection(s) is resolved; if patient develops a serious infection consider suspending treatment and using an accelerated elimination procedure; reassess benefits and risks prior to resumption of therapy; instruct patients to report symptoms of infections to a physician",
                        "Therapy not recommended for patients with severe immunodeficiency, bone marrow disease, or severe, uncontrolled infections; medications that have immunosuppression potential may cause patients to be more susceptible to infections, including opportunistic infections",
                        "One fatal case of klebsiella pneumonia sepsis reported in a patient taking this medication (14 mg) for 1.7 years; fatal infections reported in postmarketing setting in patients receiving this drug, especially Pneumocystis jirovecii pneumonia and aspergillosis",
                        "Most reports were confounded by concomitant immunosuppressant therapy and/or comorbid illness which, in addition to rheumatoid disease, may predispose patients to infection; in clinical studies, cytomegalovirus hepatitis reactivation has been observed",
                        "In clinical tirals in adult patients, cases of tuberculosis observed; prior to initiating treatment, screen patients for latent tuberculosis infection with a tuberculin skin test or with blood test for mycobacterium tuberculosis infection",
                        "This drug has not been studied in patients with a positive tuberculosis screen, and safety in individuals with latent tuberculosis infection is unknown; for patients testing positive in tuberculosis screening, treat by standard medical practice prior to administering therapy "
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Teriflunomide is CYP2C8 inhibitor, weak CYP1A2 inducer, organic anion transporter 3 (OAT3) inhibitor; BCRP and organic anion transporting polypeptide B1 and B3 (OATP1B1/1B3) inhibitor",
                        "Coadministration with CYP2C8 substrates (eg, paclitaxel, pioglitazone, repaglinide, rosiglitazone) may increase exposure to the CYP2C8 substrates",
                        "Coadministration with warfarin requires close monitoring of INR because teriflunomide may decrease peak INR by ~25%",
                        "Teriflunomide may increase the systemic exposures of ethinylestradiol and levonorgestrel; consider the type or dose of contraceptives used in combination with teriflunomide",
                        "Coadministration with OAT3 substrates may increase exposure of the OAT3 substrates",
                        "Concomitant use with CYP1A2 substrates and teriflunomide may reduce expose of the CYP1A2 substrates",
                        "Immunosuppressive or immunomodulating therapies",
                        "Coadministration with antineoplastic or immunosuppressive therapies used for treatment of multiple sclerosis has not been evaluated",
                        "When switching from teriflunomide to another agent with a known potential for hematologic suppression, monitor for hematologic toxicity, because there will be overlap of systemic exposure to both compounds",
                        "Use of an accelerated elimination procedure may decrease this risk, but may also potentially result in return of disease activity if the patient had been responding to treatment "
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "teriflunomide, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexucabtagene autoleucel",
            "description": {
                "common": "teriflunomide, brexucabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciltacabtagene autoleucel",
            "description": {
                "common": "teriflunomide, ciltacabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idecabtagene vicleucel",
            "description": {
                "common": "teriflunomide, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisocabtagene maraleucel",
            "description": {
                "common": "teriflunomide, lisocabtagene maraleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tisagenlecleucel",
            "description": {
                "common": "teriflunomide, tisagenlecleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tucatinib",
            "description": {
                "common": "teriflunomide will increase the level or effect of tucatinib by  Other (see comment). Avoid or Use Alternate Drug. Coadministration of tucatinib (a CYP2C8 substrate) with a strong or moderate CYP2C8 inhibitors increases tucatinib plasma concentrations and risk of toxicities."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alosetron",
            "description": {
                "common": "teriflunomide decreases levels of alosetron by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amiodarone",
            "description": {
                "common": "teriflunomide increases levels of amiodarone by Other (see comment). Use Caution/Monitor. \nComment: Teriflunomide inhibits CYP2C8; caution when coadministered with CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amitriptyline",
            "description": {
                "common": "teriflunomide decreases levels of amitriptyline by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "betaxolol",
            "description": {
                "common": "teriflunomide decreases levels of betaxolol by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "caffeine",
            "description": {
                "common": "teriflunomide decreases levels of caffeine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "teriflunomide increases levels of carbamazepine by Other (see comment). Use Caution/Monitor. \nComment: Teriflunomide inhibits CYP2C8; caution when coadministered with CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clomipramine",
            "description": {
                "common": "teriflunomide decreases levels of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clozapine",
            "description": {
                "common": "teriflunomide decreases levels of clozapine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclobenzaprine",
            "description": {
                "common": "teriflunomide decreases levels of cyclobenzaprine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dacarbazine",
            "description": {
                "common": "teriflunomide decreases levels of dacarbazine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dapsone",
            "description": {
                "common": "teriflunomide increases levels of dapsone by Other (see comment). Use Caution/Monitor. \nComment: Teriflunomide inhibits CYP2C8; caution when coadministered with CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diclofenac",
            "description": {
                "common": "teriflunomide increases levels of diclofenac by Other (see comment). Use Caution/Monitor. \nComment: Teriflunomide inhibits CYP2C8; caution when coadministered with CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxepin",
            "description": {
                "common": "teriflunomide decreases levels of doxepin by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "duloxetine",
            "description": {
                "common": "teriflunomide decreases levels of duloxetine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "enzalutamide",
            "description": {
                "common": "teriflunomide increases levels of enzalutamide by Other (see comment). Use Caution/Monitor. \nComment: Teriflunomide inhibits CYP2C8; caution when coadministered with CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "estradiol",
            "description": {
                "common": "teriflunomide decreases levels of estradiol by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "estrogens conjugated synthetic",
            "description": {
                "common": "teriflunomide decreases levels of estrogens conjugated synthetic by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "estrogens esterified",
            "description": {
                "common": "teriflunomide decreases levels of estrogens esterified by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "estropipate",
            "description": {
                "common": "teriflunomide decreases levels of estropipate by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethinylestradiol",
            "description": {
                "common": "teriflunomide increases levels of ethinylestradiol by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flutamide",
            "description": {
                "common": "teriflunomide decreases levels of flutamide by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluvastatin",
            "description": {
                "common": "teriflunomide increases levels of fluvastatin by Other (see comment). Use Caution/Monitor. \nComment: Teriflunomide inhibits CYP2C8; caution when coadministered with CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluvoxamine",
            "description": {
                "common": "teriflunomide will decrease the level or effect of fluvoxamine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ifosfamide",
            "description": {
                "common": "ifosfamide, teriflunomide.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isotretinoin",
            "description": {
                "common": "teriflunomide increases levels of isotretinoin by Other (see comment). Use Caution/Monitor. \nComment: Teriflunomide inhibits CYP2C8; caution when coadministered with CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lapatinib",
            "description": {
                "common": "teriflunomide increases levels of lapatinib by Other (see comment). Use Caution/Monitor. \nComment: Teriflunomide inhibits CYP2C8; caution when coadministered with CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "letermovir",
            "description": {
                "common": "teriflunomide increases levels of letermovir by decreasing metabolism. Use Caution/Monitor. Coadminstration of letermovir, an OATP1B1/3 substrate, with OATP1B1/3 inhibitors may increase letermovir plasma concentrations."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levonorgestrel intrauterine",
            "description": {
                "common": "teriflunomide increases levels of levonorgestrel intrauterine by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levonorgestrel oral",
            "description": {
                "common": "teriflunomide increases levels of levonorgestrel oral by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lomustine",
            "description": {
                "common": "lomustine and teriflunomide both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Concomitant therapy is expected to increase the risk of immunosuppression. Use caution when switching patients from long-acting therapies with immune effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metaxalone",
            "description": {
                "common": "teriflunomide increases levels of metaxalone by Other (see comment). Use Caution/Monitor. \nComment: Teriflunomide inhibits CYP2C8; caution when coadministered with CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methadone",
            "description": {
                "common": "teriflunomide increases levels of methadone by Other (see comment). Use Caution/Monitor. \nComment: Teriflunomide inhibits CYP2C8; caution when coadministered with CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mexiletine",
            "description": {
                "common": "teriflunomide decreases levels of mexiletine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mirtazapine",
            "description": {
                "common": "teriflunomide decreases levels of mirtazapine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ofatumumab SC",
            "description": {
                "common": "ofatumumab SC, teriflunomide.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with coadministration. When switching from therapies with immune effects, take into account the duration and mechanism of action of these therapies when initiating ofatumumab SC."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olanzapine",
            "description": {
                "common": "teriflunomide decreases levels of olanzapine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paclitaxel",
            "description": {
                "common": "teriflunomide increases levels of paclitaxel by Other (see comment). Use Caution/Monitor. \nComment: Teriflunomide inhibits CYP2C8; caution when coadministered with CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paclitaxel protein bound",
            "description": {
                "common": "teriflunomide increases levels of paclitaxel protein bound by Other (see comment). Use Caution/Monitor. \nComment: Teriflunomide inhibits CYP2C8; caution when coadministered with CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pazopanib",
            "description": {
                "common": "teriflunomide increases levels of pazopanib by Other (see comment). Use Caution/Monitor. \nComment: Teriflunomide inhibits CYP2C8; caution when coadministered with CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pimozide",
            "description": {
                "common": "teriflunomide decreases levels of pimozide by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pioglitazone",
            "description": {
                "common": "teriflunomide increases levels of pioglitazone by Other (see comment). Use Caution/Monitor. \nComment: Teriflunomide inhibits CYP2C8; caution when coadministered with CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pitavastatin",
            "description": {
                "common": "teriflunomide increases levels of pitavastatin by Other (see comment). Use Caution/Monitor. \nComment: Teriflunomide inhibits CYP2C8; caution when coadministered with CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propranolol",
            "description": {
                "common": "teriflunomide decreases levels of propranolol by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ramelteon",
            "description": {
                "common": "teriflunomide decreases levels of ramelteon by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rasagiline",
            "description": {
                "common": "teriflunomide decreases levels of rasagiline by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "repaglinide",
            "description": {
                "common": "teriflunomide increases levels of repaglinide by Other (see comment). Use Caution/Monitor. \nComment: Teriflunomide inhibits CYP2C8; caution when coadministered with CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "riluzole",
            "description": {
                "common": "teriflunomide decreases levels of riluzole by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ropinirole",
            "description": {
                "common": "teriflunomide decreases levels of ropinirole by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ropivacaine",
            "description": {
                "common": "teriflunomide decreases levels of ropivacaine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rosiglitazone",
            "description": {
                "common": "teriflunomide increases levels of rosiglitazone by Other (see comment). Use Caution/Monitor. \nComment: Teriflunomide inhibits CYP2C8; caution when coadministered with CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "selegiline",
            "description": {
                "common": "teriflunomide increases levels of selegiline by Other (see comment). Use Caution/Monitor. \nComment: Teriflunomide inhibits CYP2C8; caution when coadministered with CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "selegiline transdermal",
            "description": {
                "common": "teriflunomide increases levels of selegiline transdermal by Other (see comment). Use Caution/Monitor. \nComment: Teriflunomide inhibits CYP2C8; caution when coadministered with CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "selexipag",
            "description": {
                "common": "teriflunomide will increase the level or effect of selexipag by  decreasing metabolism. Modify Therapy/Monitor Closely. Reduce selexipag dose to once daily if coadministered with moderate CYP2C8 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sitagliptin",
            "description": {
                "common": "teriflunomide increases levels of sitagliptin by Other (see comment). Use Caution/Monitor. \nComment: Teriflunomide inhibits CYP2C8; caution when coadministered with CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "theophylline",
            "description": {
                "common": "teriflunomide decreases levels of theophylline by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thiothixene",
            "description": {
                "common": "teriflunomide decreases levels of thiothixene by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tizanidine",
            "description": {
                "common": "teriflunomide decreases levels of tizanidine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab",
            "description": {
                "common": "trastuzumab, teriflunomide.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab deruxtecan",
            "description": {
                "common": "trastuzumab deruxtecan, teriflunomide.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "treprostinil",
            "description": {
                "common": "teriflunomide increases levels of treprostinil by Other (see comment). Use Caution/Monitor. \nComment: Teriflunomide inhibits CYP2C8; caution when coadministered with CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tretinoin",
            "description": {
                "common": "teriflunomide increases levels of tretinoin by Other (see comment). Use Caution/Monitor. \nComment: Teriflunomide inhibits CYP2C8; caution when coadministered with CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trifluoperazine",
            "description": {
                "common": "teriflunomide decreases levels of trifluoperazine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Headache",
            "percent": "19-22"
        },
        {
            "name": "Diarrhea",
            "percent": "15-18"
        },
        {
            "name": "Increased ALT",
            "percent": "12-14"
        },
        {
            "name": "Alopecia",
            "percent": "10-13"
        },
        {
            "name": "Influenza",
            "percent": "9-12"
        },
        {
            "name": "Nausea",
            "percent": "9-14"
        },
        {
            "name": "Paresthesia",
            "percent": "9-10"
        },
        {
            "name": "Phosphatemia",
            "percent": "5-18"
        },
        {
            "name": "URTI",
            "percent": "9"
        },
        {
            "name": "Bronchitis",
            "percent": "5-8"
        },
        {
            "name": "Upper abdominal pain",
            "percent": "5-6"
        },
        {
            "name": "Sinusitis",
            "percent": "4-6"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "4-5"
        },
        {
            "name": "Hypertension",
            "percent": "4"
        },
        {
            "name": "Toothache",
            "percent": "4"
        },
        {
            "name": "Increased GGT",
            "percent": "3-5"
        },
        {
            "name": "Anxiety",
            "percent": "3-4"
        },
        {
            "name": "Myalgia",
            "percent": "3-4"
        },
        {
            "name": "Pruritus",
            "percent": "3-4"
        },
        {
            "name": "Blurred vision",
            "percent": "3"
        },
        {
            "name": "Cystitis",
            "percent": "2-4"
        },
        {
            "name": "Viral gastroenteritis",
            "percent": "2-4"
        },
        {
            "name": "Oral herpes",
            "percent": "2-4"
        },
        {
            "name": "Neutropenia",
            "percent": "2-4"
        },
        {
            "name": "Increased AST",
            "percent": "2-3"
        },
        {
            "name": "Seasonal allergy",
            "percent": "2-3"
        },
        {
            "name": "Burning sensation",
            "percent": "2-3"
        },
        {
            "name": "Palpitations",
            "percent": "2-3"
        },
        {
            "name": "Decreased weight",
            "percent": "2-3"
        },
        {
            "name": "Decreased neutrophil count",
            "percent": "2-3"
        },
        {
            "name": "Sciatica",
            "percent": "1-3"
        },
        {
            "name": "Conjunctivitis",
            "percent": "1-3"
        },
        {
            "name": "Increased WBC",
            "percent": "1-3"
        },
        {
            "name": "Acne",
            "percent": "1-3"
        },
        {
            "name": "Carpal tunnel syndrome",
            "percent": "1-3"
        },
        {
            "name": "Leukopenia",
            "percent": "1-2"
        },
        {
            "name": "Abdominal distention",
            "percent": "1-2"
        },
        {
            "name": "Cardiovascular death",
            "percent": "0.25"
        },
        {
            "name": "Hypersensitivity reactions",
            "percent": null
        },
        {
            "name": "Severe skin reactions",
            "percent": null
        },
        {
            "name": "including toxic epidermal necrolysis and Stevens",
            "percent": null
        },
        {
            "name": "Johnson syndrome",
            "percent": null
        },
        {
            "name": "drug reaction with eosinophilia and systemic symptoms",
            "percent": null
        },
        {
            "name": "Thrombocytopenia",
            "percent": null
        },
        {
            "name": "Interstitial lung disease",
            "percent": null
        },
        {
            "name": "Pancreatitis",
            "percent": null
        },
        {
            "name": "Colitis",
            "percent": null
        },
        {
            "name": "Psoriasis or worsening of psoriasis",
            "percent": null
        },
        {
            "name": "including pustular psoriasis and nail psoriasis",
            "percent": null
        },
        {
            "name": "nail disorders",
            "percent": null
        }
    ]
}